The report found that while turning to income from outpatient specialty drugs “will help boost margins, its sustainability will be uncertain,” especially given the increased effort by legislators, regulators and commercial insurers to rein in specialty drug spending.
“Recent regulatory and legislative proposals, if adopted, would put downward pressure on drug prices and potentially reduce hospitals’ income from the purchase of outpatient specialty drugs,” Moody’s wrote.
Moody’s said that hospitals eligible for the 340B drug discount program will receive the most benefit from purchasing and generating income from outpatient specialty drugs, because they “receive much larger discounts on the price of eligible outpatient drugs purchased for all patients, regardless of how they are insured.”
However, this also places 340B-eligible hospitals, which would depend more heavily on income from the drugs, most at-risk, according to the report.
Moody’s also found that an increasing number of 340B hospitals will expand or build in-house specialty pharmacies to dispense drugs and add to income growth.
More articles on pharmacy:
Novant Health leaders talk Walgreens partnership goals for 2020
Sanofi recalls heartburn drug over cancer risks
Centura Health opens retail pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.